$130.52
+0.21%ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ICUI โข NASDAQ
| ICU Medical, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
2.2B | 2.4B | 2.3B | 2.3B | 1.3B | 1.3B | 1.3B | 1.4B | 1.3B | 379.4M | 341.7M | 309.3M | 313.7M | 316.9M | 302.2M | 284.6M | 231.5M | 204.7M | 188.1M | 201.6M | |
GROSS PROFIT | ||||||||||||||||||||
(1.4B) | (1.6B) | (1.5B) | (1.6B) | (824.8M) | (809.5M) | (794.3M) | (830M) | (866.5M) | (178M) | (160.9M) | (157.9M) | (159M) | (160.4M) | (159.8M) | (154M) | (122.7M) | (114.9M) | (109.9M) | (120.9M) | |
819.7M | 824.8M | 739.9M | 697.8M | 491.5M | 461.5M | 471.9M | 570M | 426.1M | 201.4M | 180.8M | 151.4M | 154.7M | 156.5M | 142.4M | 130.6M | 108.8M | 89.8M | 78.2M | 80.7M | |
OPERATING INCOME | ||||||||||||||||||||
(712.7M) | (781.8M) | (717M) | (740.7M) | (368.2M) | (363.3M) | (364.5M) | (381M) | (355.2M) | (102.4M) | (98.9M) | (107.3M) | (102.8M) | (95.2M) | (93.9M) | (81.3M) | (70.9M) | (58.4M) | (53.6M) | (49.8M) | |
(625.2M) | (638.8M) | (606.7M) | (608.3M) | (302.6M) | (284M) | (277M) | (328.1M) | (304M) | (89.4M) | (83.2M) | (88.9M) | (90.4M) | (84.6M) | (85.3M) | (76.6M) | (68.2M) | (53.6M) | (45.5M) | (44.2M) | |
(87.5M) | (88.6M) | (85.3M) | (93M) | (47.5M) | (42.9M) | (48.6M) | (52.9M) | (51.3M) | (13M) | (15.7M) | (18.3M) | (12.4M) | (10.6M) | (8.6M) | (4.7M) | (2.6M) | (4.8M) | (8.1M) | (7.7M) | |
107M | 43M | 22.8M | -42.9M | 123.2M | 98.2M | 107.4M | 21.6M | -15.1M | 82.9M | 68.6M | 39M | 51.9M | 61.3M | 65.2M | 49.3M | 38M | 31.4M | 24.6M | 30.9M | |
PRE-TAX INCOME | ||||||||||||||||||||
(105.4M) | (106.5M) | (102.7M) | (70.8M) | (858K) | (1.8M) | (549K) | (709K) | (2M) | (118K) | (39K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-95.1M | -95.8M | -95.2M | -66.4M | 2M | 1.9M | -549K | -709K | -2M | -118K | -39K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (54.4M) | (25M) | (39.3M) | (18.2M) | (36.4M) | (38.9M) | (1.5M) | -2.5M | (767K) | (0.0) | (755K) | (765K) | (563K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -2.1M | |
-103.8M | -109M | -101.1M | -71.5M | -59K | -668K | 7.3M | -7.4M | 64.6M | 2.2M | 1.1M | 755K | 765K | 563K | 1.2M | 129K | 1.2M | 4.7M | 8.7M | 4.5M | |
3.2M | -66M | -78.3M | -114.4M | 123.2M | 97.5M | 114.7M | 22.4M | 51.3M | 85.2M | 69.7M | 39.8M | 52.7M | 61.8M | 66.4M | 49.4M | 39.1M | 36.1M | 33.3M | 35.3M | |
NET INCOME | ||||||||||||||||||||
(2.4M) | (51.7M) | -48.6M | -40.1M | (20.1M) | (10.6M) | (13.7M) | -6.4M | -17.4M | (22.1M) | (24.7M) | (13.5M) | (12.3M) | (20.6M) | (21.8M) | (18.5M) | (12.6M) | (11.8M) | (10.3M) | (10.2M) | |
732K | -117.7M | -29.7M | -74.3M | 103.1M | 86.9M | 101M | 28.8M | 68.6M | 63.1M | 45M | 26.3M | 40.4M | 41.3M | 44.7M | 30.9M | 26.6M | 24.3M | 23.1M | 25.7M |
ICUI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 |
Continue your ICUI research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.